Next Article in Journal
Ubiquitin in Influenza Virus Entry and Innate Immunity
Next Article in Special Issue
Studies in a Murine Model Confirm the Safety of Griffithsin and Advocate Its Further Development as a Microbicide Targeting HIV-1 and Other Enveloped Viruses
Previous Article in Journal
The Microtubule Inhibitor Podofilox Inhibits an Early Entry Step of Human Cytomegalovirus
Previous Article in Special Issue
A Designed “Nested” Dimer of Cyanovirin-N Increases Antiviral Activity
Review

Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential

Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Barry R. O’Keefe
Viruses 2016, 8(10), 296; https://doi.org/10.3390/v8100296
Received: 2 September 2016 / Revised: 10 October 2016 / Accepted: 13 October 2016 / Published: 24 October 2016
(This article belongs to the Special Issue Lectins as Antiviral)
Griffithsin (GRFT), an algae-derived lectin, is one of the most potent viral entry inhibitors discovered to date. It is currently being developed as a microbicide with broad-spectrum activity against several enveloped viruses. GRFT can inhibit human immunodeficiency virus (HIV) infection at picomolar concentrations, surpassing the ability of most anti-HIV agents. The potential to inhibit other viruses as well as parasites has also been demonstrated. Griffithsin’s antiviral activity stems from its ability to bind terminal mannoses present in high-mannose oligosaccharides and crosslink these glycans on the surface of the viral envelope glycoproteins. Here, we review structural and biochemical studies that established mode of action and facilitated construction of GRFT analogs, mechanisms that may lead to resistance, and in vitro and pre-clinical results that support the therapeutic potential of this lectin. View Full-Text
Keywords: carbohydrate binding agent; viral envelope glycoproteins; multivalency; resistance; immunogenicity; HIV; HSV; HCV carbohydrate binding agent; viral envelope glycoproteins; multivalency; resistance; immunogenicity; HIV; HSV; HCV
Show Figures

Graphical abstract

MDPI and ACS Style

Lusvarghi, S.; Bewley, C.A. Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential. Viruses 2016, 8, 296. https://doi.org/10.3390/v8100296

AMA Style

Lusvarghi S, Bewley CA. Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential. Viruses. 2016; 8(10):296. https://doi.org/10.3390/v8100296

Chicago/Turabian Style

Lusvarghi, Sabrina, and Carole A. Bewley 2016. "Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential" Viruses 8, no. 10: 296. https://doi.org/10.3390/v8100296

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop